Science Explorer Back to mapMap
Discussion
Researcher · Lexicon Pharmaceuticals (United States) · United States

Brian Zambrowicz

Brian Zambrowicz publishes mostly in Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery, on topics such as Diabetes Treatment and Management, Pancreatic function and diabetes and CRISPR and Genetic Engineering.

ORCID 0000-0001-8831-0406 OpenAlex
World rank
#62,950
of 7,710,434 ranked researchers
Rank in United States
#24,216
of 1,627,098
Works
144
Citations
14k
Citations per work
100.3
h-index
55
i10-index 93Top 2.7% in Molecular Biology
Brian Zambrowicz

What does Brian Zambrowicz research?

Brian Zambrowicz's work is mostly in Biochemistry, Genetics and Molecular Biology (36%), Medicine (27%).

Everything else: 54 works · 37.3% of their workLife Sciences: 51 works · 35.6% of their workBiochemistry, Genetics and Molecular Biology: 51 works · 35.6% of their workMolecular Biology: 41 works · 28.5% of their workGenetics: 10 works · 7.1% of their workHealth Sciences: 39 works · 27.1% of their workMedicine: 39 works · 27.1% of their workEndocrinology, Diabetes and Metabolism: 16 works · 11.3% of their workSurgery: 11 works · 7.3% of their workEpidemiology: 8 works · 5.5% of their workNeurology: 4 works · 3.0% of their workTHEIR WORKBrian Zambrowicz144works
Life Sciences36%Health Sciences27%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else5437.3%
    1. Biochemistry, Genetics and Molecular Biology5135.6%
    1. Medicine3927.1%
  1. 1Molecular Biology28% of their works
  2. 2Endocrinology, Diabetes and Metabolism11% of their works
  3. 3Surgery7% of their works
  4. 4Genetics7% of their works
  5. 5Epidemiology6% of their works
  6. 6Neurology3% of their works

Research topics

Which keywords describe Brian Zambrowicz's research?

The keywords of their largest research topics: Cardiovascular Outcomes, Genetic Mutations, Type 2 Diabetes, Pancreatic Islets, ß-Cell Dysfunction, Genome Engineering, RNA-Guided and Neuroendocrine Tumors.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Cardiovascular Outcomes231 topic
  2. Genetic Mutations232 topics
  3. Type 2 Diabetes231 topic
  4. Pancreatic Islets201 topic
  5. ß-Cell Dysfunction201 topic
  6. Genome Engineering181 topic
  7. RNA-Guided181 topic
  8. Neuroendocrine Tumors141 topic
  9. Pancreatic Neuroendocrine Tumors141 topic
  10. AMP-Activated Protein Kinase101 topic
  11. Cushing's Syndrome101 topic
  12. Genetic Modification101 topic
  13. Metformin101 topic
  14. Pituitary Adenomas101 topic
  15. Transgenic Animals101 topic
  16. ALK91 topic
  17. Neuroblastoma91 topic

Where does Brian Zambrowicz work?

Brian Zambrowicz's main affiliation in the publication record is Lexicon Pharmaceuticals (United States), United States.

How many publications and citations does Brian Zambrowicz have?

OpenAlex counts 144 works and 14,446 citations for Brian Zambrowicz, an h-index of 55, ranking #62,950 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Brian Zambrowicz. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.